Pfizer cuts Norway's COVID-19 vaccine deliveries, rollout delayed
Reuters
Published Jun 10, 2021 21:53
OSLO (Reuters) - Pfizer (NYSE:PFE) has cut July deliveries of its COVID-19 vaccine to Norway by 400,000 doses, delaying the Nordic country's vaccine rollout, the company and the Norwegian Institute of Public Health (FHI) told Reuters on Thursday.
The news was first reported by Norwegian daily VG, citing Pfizer's Norwegian arm, and Geir Bukholm, Director of Infection Prevention and Control at the Norwegian Institute of Public Health.
Pfizer, a major provider of vaccines to Norway which has dropped Astrazeneca (LON:AZN)'s jab and only offering J&J (NYSE:JNJ)'s Jenssen vaccine under certain conditions, will now provide 800,000 doses in July, from the earlier estimated 1.2 million doses, Pfizer Norway confirmed to Reuters.
As a consequence, Norway's vaccination programme will be delayed by one to two weeks compared to its earlier estimate, FHI said.
Prime Minister Erna Solberg said on May 12 the government aimed to offer a first dose to all those aged 18 and over by July 25.
Get The App
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.